Fierce Pharma March 4, 2024
Zoey Becker

After the U.S. government last month floated its first offers for 10 drugs on Medicare as part of the negotiations process laid out in the Inflation Reduction Act (IRA), the pricing talks are now in full swing.

Every drugmaker with a product on the list has responded to the government’s Feb. 1 pricing offer with a counteroffer, the Department of Health and Human Services (HHS) said in a Monday press release.

The agency is pleased with the “good-faith, up front negotiations,” HHS Secretary Xavier Becerra said in the release. “We are committed to constructive dialogue and are glad the drug companies are coming to the table.”

The industry, for its part, has routinely voiced complaints about a “lack of transparency”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
Machine learning reveals how metabolite profiles predict aging and health
The weight loss drug revolution is shrinking America's waistline
2024’s Biggest Weight Loss Drug Stories
Five Breakthroughs In 2024 That Laid A Foundation For Future Tech

Share This Article